In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Amgen Licenses IL-33 Inhibitor For Asthma, COPD To Genentech

This article was originally published in Scrip

Executive Summary

Amgen Inc. will continue to sharpen its focus on six key therapeutic areas by licensing its Phase I interleukin-33 (IL-33) inhibitor AMG 282 to the Roche company Genentech Inc., which will study the monoclonal antibody in asthma and chronic obstructive pulmonary disease (COPD).






Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts